Cargando…

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a randomized trial against placebo. Zeidan and colleagues report that after a median of 26 months follow-up, 27% of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeidan, Amer M., Platzbecker, Uwe, Garcia-Manero, Guillermo, Sekeres, Mikkael A., Fenaux, Pierre, DeZern, Amy E., Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit K., Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Shetty, Jeevan K., Ito, Rodrigo, Zhang, Jennie, Zhang, George, Ha, Xianwei, Backstrom, Jay T., Komrokji, Rami S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Letter to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653038/ https://www.ncbi.nlm.nih.gov/pubmed/35797468 http://dx.doi.org/10.1182/blood.2022016171

Ejemplares similares

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
por: Della Porta, Matteo Giovanni, et al.
Publicado: (2023)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
por: Nazha, Aziz, et al.
Publicado: (2017)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes
por: Patel, Jay L., et al.
Publicado: (2020)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
por: Sekeres, Mikkael, et al.
Publicado: (2023)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
por: Platzbecker, U, et al.
Publicado: (2014)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
por: Visconte, Valeria, et al.
Publicado: (2014)

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023)

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione
por: North, Anne K., et al.
Publicado: (2020)

Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)
por: Ohba, Rie, et al.
Publicado: (2012)

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2022)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Gaucher-like cells in myelodysplastic syndrome with ring sideroblasts
por: El Khoury, Christelle, et al.
Publicado: (2022)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
por: Stahl, Maximilian, et al.
Publicado: (2023)

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
por: Weeks, Lachelle D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_63mnmept818mjthqrvtevlkuna